# A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

> **NCT07625280** · PHASE3 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Narcolepsy
- Idiopathic Hypersomnia

## Interventions

- **DRUG:** Xywav
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07625280
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2027-12-23
- **Final completion:** 2028-01-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625280, "A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*